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Abstract
In this opinion, the EFSA GMO Panel assesses the ﬁve-event stack maize and 20 of its subcombinations
independently of their origin. The EFSA GMO Panel has previously assessed the ﬁve single events that are
combined to produce this ﬁve-event stack maize Bt11 9 59122 9 MIR604 9 1507 9 GA21 and did not
identify safety concerns. No new data on the single events, leading to a modiﬁcation of the original
conclusions on their safety, were identiﬁed. The molecular, agronomic, phenotypic and compositional
data on the ﬁve-event stack maize did not give rise to safety concerns and there is no reason to expect
interactions between the single events impacting on the food and feed safety of the ﬁve-event stack
maize. Considering the scope of the application (no cultivation), routes of exposure and limited exposure
levels, the Panel concludes that this ﬁve-event stack maize would not raise safety concerns in the event of
accidental release of viable grains into the environment. The EFSA GMO Panel concludes that the ﬁve-
event stack maize is as safe and as nutritious as its conventional counterpart in the context of its scope.
For the 20 subcombinations, the EFSA GMO Panel followed a weight-of-evidence approach, and
concluded that they are expected to be as safe as the ﬁve-event stack maize. No speciﬁc data were
submitted for the subcombinations included in the scope of this application that could be produced by
conventional crossing through targeted breeding approaches. In order to reduce the consequent
uncertainties and to conﬁrm assumptions made for their assessment, the EFSA GMO Panel considers that
the applicant should provide relevant information, if these subcombinations were to be created via
targeted breeding approaches and imported into the EU in the future. In this case, this information
should focus on expression levels of the newly expressed proteins.
A minority opinion expressed by an EFSA GMO Panel member is appended to this opinion.
© 2016 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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Summary
Following the submission of application EFSA-GMO-DE-2011-99 under Regulation (EC) No 1829/2003
from Syngenta, the Panel on Genetically Modiﬁed Organisms of the European Food Safety Authority
(hereafter referred as EFSA GMO Panel) was asked to deliver a scientiﬁc opinion on the safety of
herbicide-tolerant and insect-resistant genetically modiﬁed maize Bt11 9 59122 9 MIR604 9
1507 9 GA21 (referred to hereafter as ‘ﬁve-event stack maize’) and 20 subcombinations (referred to as
‘subcombinations independently of their origin’ in line with the Commission implementing regulation (EU)
No 503/2013). The scope of application EFSA-GMO-DE-2011-99 is for food and feed uses, import and
processing, but excludes cultivation within the European Union (EU).
The term ‘subcombination’ refers to any combination of up to four of the events present in the ﬁve-
event stack maize Bt11 9 59122 9 MIR604 9 1507 9 GA21. Subcombinations occur as segregating
progeny in the harvested grains of Bt11 9 59122 9 MIR604 9 1507 9 GA21 (embryo and albumen),
and their safety is evaluated within the assessment of the ﬁve-event stack maize Bt11 9 59122 9
MIR604 9 1507 9 GA21 in Section 3.4 of the present opinion.
‘Subcombination’ also refers to any combination of up to four of the events Bt11, 59122, MIR604,
1507 or GA21 that has either been or could be produced by conventional crossing, through targeted
breeding approaches (EFSA GMO Panel, 2011). These are maize stacks that can be bred, produced
and marketed independently of the ﬁve-event stack maize Bt11 9 59122 9 MIR604 9 1507 9 GA21.
These stacks, including their segregating progeny, are risk assessed in Section 3.5 of the present
opinion.
In accordance with the EFSA GMO Panel guidance document applicable to this application (EFSA,
2006, 2007a), ‘where all single events have been assessed, the risk assessment of stacked events
should focus mainly on issues related to (a) stability, (b) expression of the events and (c) potential
interactions between the events’. For application EFSA-GMO-DE-2011-99, previous assessments of the
ﬁve single events (Bt11, 59122, MIR604, 1507 and GA21) provided a basis to evaluate the ﬁve-event
stack maize and the 20 subcombinations.
The ﬁve-event stack maize Bt11 9 59122 9 MIR604 9 1507 9 GA21 was produced by conventional
crossing to combine ﬁve single maize events. Maize containing the single events, Bt11 (expressing
Cry1Ab and PAT proteins), 59122 (expressing Cry34Ab1, Cry35Ab1 and PAT proteins), MIR604
(expressing mCry3A and PMI proteins), 1507 (producing Cry1F and PAT proteins) and GA21 (expressing
mEPSPS protein), were assessed previously and no concerns were identiﬁed. No safety issue was
identiﬁed by updated bioinformatic analyses nor reported by the applicant concerning the ﬁve single
maize events, since the publication of the scientiﬁc opinions. Consequently, the EFSA GMO
Panel considers that its previous conclusions on the safety of the single maize events remain valid
(Section 3.2).
For the ﬁve-event stack maize, the risk assessment included the molecular characterisation of the
inserted DNA and the analysis of the proteins expression. An evaluation of the comparative analyses of
compositional, agronomic and phenotypic characteristics was undertaken, and the safety of the newly
expressed proteins and the whole food/feed was evaluated with respect to potential toxicity,
allergenicity and nutritional characteristics. The evaluation of environmental impacts and the post-
market environmental monitoring (PMEM) plan was also undertaken.
The molecular data establish that the transformation events stacked in maize Bt11 9 59122 9
MIR604 9 1507 9 GA21 have the same molecular properties and characteristics as the single
transformation events. Protein expression analyses showed that the levels of the newly expressed
proteins are similar in the ﬁve-event stack and the single events, with the exception of PMI.
Comparison of the levels of the newly expressed proteins between the ﬁve-event stack and the
respective single events did not reveal an interaction that would affect protein expression level.
The newly expressed proteins in the ﬁve-event stack maize did not raise concerns for human and
animal health. The compositional data indicate that maize Bt11 9 59122 9 MIR604 9 1507 9 GA21
would be expected to deliver the same nutritional characteristics as its conventional counterpart. This
was conﬁrmed by the results of an animal feeding study in chickens for fattening.
The Panel on Genetically Modiﬁed Organisms of the European Food Safety Authority (EFSA GMO
Panel) considers that there is no reason to expect interactions that could impact on the food and feed
safety. No safety concerns are foreseen for any of the 20 subcombinations not previously assessed by
EFSA.
Considering the combined events, the outcome of the comparative analysis, the routes of exposure
and the limited exposure levels, the EFSA GMO Panel concluded that this ﬁve-event stack maize would
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not raise safety concerns in the event of accidental release of viable GM maize grains into the
environment.
In conclusion, the EFSA GMO Panel is of the opinion that the ﬁve-event stack maize is as safe and
as nutritious as its conventional counterpart and non-GM commercial maize varieties in the context of
its scope.
No scientiﬁc information regarding the subcombinations covered in the scope of this application
was retrieved in a literature search covering the period since the publication of the respective scientiﬁc
opinions.
The EFSA GMO Panel did not ﬁnd indication that the subcombinations, resulting from combination
of any of the single events included in the ﬁve-event stack maize, would raise safety concerns.
However, for all 20 subcombinations (Table 1) that could be produced by conventional crossing
through targeted breeding approaches, no speciﬁc data were submitted. For these, the EFSA GMO
Panel has drawn conclusions on a weight-of-evidence approach, which identiﬁed uncertainties due to
data gaps. In order to reduce these uncertainties and to conﬁrm assumptions made for the
assessment of these subcombinations, the EFSA GMO Panel considers that the applicant should
provide relevant information, if these subcombinations were to be created via targeted breeding
approaches and imported into the EU in the future. In this case, this information should focus on
expression levels of the newly expressed proteins.
The EFSA GMO Panel considers that post-market monitoring of GM food/feed is not necessary,
given the absence of safety concerns identiﬁed for the ﬁve-event stack maize and the 20 lower
subcombinations. If these subcombinations were to be created via targeted breeding approaches and
imported into the EU, the requirement for monitoring should be considered on the basis of the new
protein expression data provided.
The EFSA GMO Panel is of the opinion that the PMEM plans provided by the applicant are in line
with the scope of the ﬁve-event stack maize and the 20 subcombinations.
In delivering its scientiﬁc opinion, the EFSA GMO Panel considered the data available on the ﬁve-
event stack maize and the single events, the scientiﬁc comments submitted by the Member States and
the relevant scientiﬁc publications.
A minority opinion expressed by an EFSA GMO Panel member is presented in the Appendix A of this
opinion.
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1. Introduction
1.1. Background
On 7 July 2011, the European Food Safety Authority (EFSA) received from the Competent Authority of
Germany an application EFSA-GMO-DE-2011-99 for authorisation of genetically modiﬁed (GM) maize
Bt11 9 59122 9 MIR604 9 1507 9 GA21 (referred to hereafter as ﬁve-event stack maize), submitted by
Syngenta Crop Protection AG (referred to hereafter as the applicant) within the framework of Regulation
(EC) No 1829/20031, for food and feed uses, import and processing. Subsequently, the applicant
requested twice, EFSA to consider a modiﬁcation in the scope of application EFSA-GMO-DE-2011-99. The
risk assessment presented here is for application EFSA-GMO-DE-2011-99 for the placing on the market of
GM maize Bt11 9 59122 9 MIR604 9 1507 9 GA21 and subcombinations that have not been
authorised previously (Table 1), independently of their origin, for food and feed uses, import and
processing.
After receiving the application EFSA-GMO-DE-2011-99 and in accordance with Articles 5(2)(b) and
17(2)(b) of Regulation (EC) No 1829/2003, EFSA informed Member States and the European
Commission, and made the summary of the application available to the public on the EFSA website.
EFSA initiated a formal review of the application to check compliance with the requirements laid down
in Articles 5(3) and 17(3) of Regulation (EC) No 1829/2003. On 21 December 2011 and 2 April 2012,
EFSA received additional information (requested on 17 August 2011 and 25 January 2012,
respectively). On 14 June 2012, EFSA declared the application valid in accordance with Articles 6(1)
and 18(1) of Regulation (EC) No 1829/2003.
EFSA made the valid application available to the Member States and the European Commission, and
consulted nominated risk assessment bodies of the Member States, including the national Competent
Authorities within the meaning of Directive 2001/18/EC2 following the requirements of Articles 6(4)
and 18(4) of Regulation (EC) No 1829/2003, to request their scientiﬁc opinion. The Member States
had 3 months after the date of receipt of the valid application (until 18 September 2012) to make their
opinion known.
The EFSA GMO Panel carried out an evaluation of the scientiﬁc risk assessment of the ﬁve-event
stack maize and subcombinations that have not been authorised previously (Table 1) (referred to as
‘subcombinations independently of their origin’ according to the Commission Implementing Regulation
(EU) No 503/20133). On 3 March 2013, 23 June 2014, 30 September 2014, 21 November 2014, 27
July 2015, 24 September 2015 and 4 April 2016, EFSA received additional information (requested on 7
December 2012, 5 February 2013, 23 September 2013, 12 March 2014, 27 October 2014, 19
September 2015 and 23 December 2015, respectively). The applicant provided additional information
spontaneously on 28 July 2014, 21 July 2015 and 17 December 2015.
In giving its Scientiﬁc Opinion to the European Commission, the Member States and the applicant,
and in accordance with Articles 6(1) and 18(1) of Regulation (EC) No 1829/2003 (European
Commission, 2003), EFSA has endeavoured to respect a time limit of 6 months from the
acknowledgement of the valid application. As additional information was requested by the EFSA GMO
Panel, the time limit of 6 months was extended accordingly, in line with Articles 6(1), 6(2), 18(1) and
18(2) of Regulation (EC) No 1829/2003.
According to Regulation (EC) No 1829/2003 (European Commission, 2003), this scientiﬁc opinion is
to be seen as the report requested under Articles 6(6) and 18(6) of that Regulation, and thus will be
part of the EFSA overall opinion in accordance with Articles 6(5) and 18(5).
1.2. Terms of Reference as provided by the requestor
The EFSA GMO Panel was requested to carry out a scientiﬁc risk assessment of ‘maize
Bt11 9 59122 9 MIR604 9 1507 9 GA21 and twenty subcombinations of the single events (Table 1),
independently of their origin’ for food and feed uses, import and processing in accordance with Articles
6(6) and 18(6) of Regulation (EC) No 1829/2003.
1 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modiﬁed
food and feed. OJ L 268, 18.10.2003, p. 1–23.
2 Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the
environment of genetically modiﬁed organisms and repealing Council Directive 90/220/EEC. OJ L 106, 12.3.2001, p. 1–38.
3 Commission Implementing Regulation (EU) No 503/2013 of 3 April 2013 on applications for authorisation of genetically
modiﬁed food and feed in accordance with Regulation (EC) No 1829/2003 of the European Parliament and of the Council and
amending Commission Regulations (EC) No 641/2004 and (EC) No 1981/2006. OJ L157, 8.6.2013, p. 1–48.
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Where applicable, any conditions or restrictions which should be imposed on the placing on the
market and/or speciﬁc conditions or restrictions for use and handling, including post-market monitoring
requirements based on the outcome of the risk assessment and, in the case of GMOs or food/feed
containing or consisting of GMOs, conditions for the protection of particular ecosystems/environment
and/or geographical areas should be indicated in accordance with Articles 6(5)(e) and 18(5)(e) of
Regulation (EC) No 1829/2003.
The EFSA GMO Panel was not requested to give an opinion on information required under Annex II
to the Cartagena Protocol. Furthermore, the EFSA GMO Panel did not consider proposals for labelling
and methods of detection (including sampling and the identiﬁcation of the speciﬁc transformation
event in the food/feed and/or food/feed produced from it), which are matters related to risk
management.
2. Data and methodologies
2.1. Data
In delivering its scientiﬁc opinion, the GMO Panel took into account the application EFSA-GMO-DE-
2011-99, additional information provided by the applicant, scientiﬁc comments submitted by the
Member States and relevant scientiﬁc publications.
2.2. Methodologies
The GMO Panel carried out a scientiﬁc risk assessment of maize Bt11 9 59122 9 MIR604 9
1507 9 GA21 and 20 subcombinations that have not been authorised previously, independently of
their origin (Table 1), for food and feed uses, import and processing in accordance with Articles 6(6)
and 18(6) of Regulation (EC) No 1829/2003. The GMO Panel took into account the appropriate
principles described in its guidelines for the risk assessment of GM plants and derived food and feed
(EFSA, 2006, 2007a; EFSA GMO Panel, 2011), for the environmental risk assessment (ERA) of GM
plants (EFSA GMO Panel, 2010) and for the post-market environmental monitoring (PMEM) of GM
plants (EFSA, 2011a).
The comments raised by the Member States are addressed in Annex G of EFSA’s overall opinion
and were taken into consideration during the scientiﬁc risk assessment.4
3. Assessment
3.1. Introduction
This application EFSA-GMO-DE-2011-99 covers 21 events: the ﬁve-event stack maize
Bt11 9 59122 9 MIR604 9 1507 9 GA21 and 20 subcombinations that have not been authorised
previously, independently of their origin (Table 1). The scope of this application is for food and feed
uses, import and processing, and excludes cultivation within the European Union (EU). The term
‘subcombination’ refers to 20 combinations of up to four of the events present in the ﬁve-event stack
maize. Subcombinations occur as segregating progeny in harvested grains of the ﬁve-event stack
maize, and their safety is part of the assessment of the ﬁve-event stack maize in Section 3.3 of this
EFSA GMO Panel Scientiﬁc Opinion.
‘Subcombination’ also refers to combinations of four, three or two of the ﬁve events Bt11, 59122,
MIR604, 1507 and GA21 that have either been or could be produced by conventional crossing through
targeted breeding approaches (EFSA GMO Panel, 2011). These are maize stacks that can be bred,
produced and marketed independently of the ﬁve-event stack maize. These subcombinations, except
for four two-event stack maize events and a three-event stack maize event, that are not in the scope
of this application, are risk assessed in Section 3.4 of this EFSA GMO Panel Scientiﬁc Opinion.
The ﬁve-event stack maize was developed to achieve insect resistance and herbicide tolerance to
glyphosate- and glufosinate ammonium-based herbicides. The insect resistance confers protection
against speciﬁc lepidopteran (e.g. Ostrinia nubilalis (European corn borer) and Sesamia nonagrioides
(Mediterranean corn borer)) and coleopteran pests (Diabrotica spp. (corn rootworm larvae)).
4 Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionDocumentsLoader?question=EFSA-Q-2011-00894
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All ﬁve single maize events Bt11, 59122, MIR604, 1507 and GA21 and ﬁve of the maize stacks have
been previously assessed (see Table 2). No concerns for human and animal health, or environmental
safety were identiﬁed.
Table 1: Twenty-one maize events covered by the scope of the application EFSA-GMO-DE-2011-99
Degree of
stacking Events Unique identiﬁers
Five-event
stack maize
Bt11 9 59122 9 MIR604 9 1507 9 GA21 SYN-BTØ11-1 9 DAS-59122-7 9 SYN-IR6Ø4-5 9
DAS-Ø15Ø7-1 9 MON-ØØØ21-9
Four-event
stack maize
Bt11 9 MIR604 9 1507 9 GA21 SYN-BTØ11-1 9 SYN-IR6Ø4-5 9 DAS-Ø15Ø7-1 9
MON-ØØØ21-9
Bt11 9 59122 9 1507 9 GA21 SYN-BTØ11-1 9 SYN-IR162-4 9 DAS-Ø15Ø7-1 9
MON-ØØØ21-9
Bt11 9 59122 9 MIR604 9 GA21 SYN-BTØ11-1 9 DAS-59122-7 9 SYN-IR6Ø4- 9
MON-ØØØ21-9
Bt11 9 59122 9 MIR604 9 1507 SYN-BTØ11-1 9 DAS-59122-7 9 SYN-IR6Ø4-5 9
DAS-Ø15Ø7-1
59122 9 MIR604 9 1507 9 GA21 DAS-59122-7 9 SYN-IR6Ø4-5 9 DAS-Ø15Ø7-1 9
MON-ØØØ21-9
Three-event
stack maize
Bt11 9 59122 9 MIR604 SYN-BTØ11-1 9 DAS-59122-7 9 SYN-IR6Ø4-5
Bt11 9 59122 9 1507 SYN-BTØ11-1 9 DAS-59122-7 9 Ø15Ø7-1
Bt11 9 59122 9 GA21 SYN-BTØ11-1 9 DAS-59122-7 9 MON-ØØØ21-9
Bt11 9 MIR604 9 1507 SYN-BTØ11-1 9 SYN-IR6Ø4-5 9 DAS-Ø15Ø7-1
Bt11 9 1507 9 GA21 SYN-BTØ11-1 9 DAS-Ø15Ø7-1 9 MON-ØØØ21-9
59122 9 MIR604 9 1507 DAS-59122-7 9 SYN-IR6Ø4-5 9 DAS-Ø15Ø7-1
59122 9 MIR604 9 GA21 DAS-59122-7 9 SYN-IR6Ø4-5 9 MON-ØØØ21-9
59122 9 1507 9 GA21 DAS-59122-7 9 DAS-Ø15Ø7-1 9 MON-ØØØ21-9
MIR604 9 1507 9 GA21 SYN-IR6Ø4-5 9 DAS-Ø15Ø7-1 9 MON-ØØØ21-9
Two-event
stack maize
Bt11 9 59122 SYN-BTØ11-1 9 DAS-59122-7
Bt11 9 1507 SYN-BTØ11-1 9 DAS-Ø15Ø7-1
59122 9 MIR604 DAS-59122-7 9 SYN-IR6Ø4-5
59122 9 GA21 DAS-59122-7 9 MON-ØØØ21-9
MIR604 9 1507 SYN-IR6Ø4-5 9 DAS-Ø15Ø7-1
1507 9 GA21 DAS-Ø15Ø7-1 9 MON-ØØØ21-9
Table 2: Single maize events and maize stacks already assessed by the EFSA GMO Panel
Events Application or mandate EFSA Scientiﬁc Opinions
Bt11 C/F/96/05.10 2005a
EFSA-GMO-RX-Bt11 2009a
EFSA-M-2012–0232(a) 2012b
59122 EFSA-GMO-NL-2005-12 2007c
EFSA-GMO-NL-2005-23 2013
MIR604 EFSA-GMO-UK-2005-11 2009d
1507 C/NL/00/10 2004
C/ES/01/01 2005b
EFSA-GMO-RX-1507 2009c
GA21 EFSA-GMO-UK-2005-19 2007b
EFSA-GMO-RX-GA21 2007b
EFSA-GMO-UK-2008-60 2011b
59122 9 1507 EFSA-GMO-NL-2005-15 2009b
MIR604 9 GA21 EFSA-GMO-UK-2007-48 2010a
EFSA-GMO-DE-2009-66 2015a
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The EFSA GMO Panel Guidance Documents establish the principle that ‘where all single events have
been assessed, the risk assessment of stacked events should focus mainly on issues related to (a)
stability, (b) expression of the events and (c) potential interactions between the events’ (EFSA, 2007a;
EFSA GMO Panel, 2011).
3.2. Updated information on single events
Since the publication of the scientiﬁc opinions on the single maize events by the EFSA GMO
Panel (EFSA, 2004, 2005a, 2007b, 2009b; EFSA GMO Panel, 2013), no safety issue pertaining to the
ﬁve single events has been reported by the applicant.
For events MIR604 and GA21, updated nucleotide sequence information was received.5 In the case of
event MIR604, a single nucleotide difference was identiﬁed in the non-coding region of the insert as
compared with the sequence originally reported in 2005. Further analyses demonstrated that this
nucleotide difference had already been present in the original material used for the risk assessment of
maize MIR604. In the case of event GA21, new sequence information revealed a nucleotide change in
the actin promoter of copy 6, a three-base pair deletion contiguous to one nucleotide substitution within
the 30 insert ﬂanking region and a difference in the number of complete mepsps (5-enolpyruvylshikimate-
3-phosphate synthase) cassettes present within the insert. Similar to event MIR604, further analyses
demonstrated that these differences had already been present in the original material used for the risk
assessment of maize GA21. The EFSA GMO Panel has performed the risk assessment of the new
sequencing information for events MIR604 and GA21 in the frame of a request received from the
European Commission6 and concluded that the original risk assessments of events MIR604 and GA21 as
a single and as a part of stacked events remains valid (EFSA GMO Panel, 2015b,c).
Bioinformatic analyses on the junction regions for events Bt11, 59122, MIR604, 1507 and GA21,
using the most up-to-date nucleotide sequences and methodology speciﬁed in the EFSA 2011 guidance
(EFSA GMO Panel, 2011), conﬁrmed that no known endogenous genes were disrupted by any of the
inserts.7
Updated bioinformatic analyses of the amino acid sequence of the newly expressed Cry1Ab,
Cry34Ab1, Cry35Ab1, mCry3A, Cry1F, PAT, PMI and mEPSPS proteins revealed no signiﬁcant similarities
to toxins and allergens.7 In addition, updated bioinformatics analyses of the newly created open
reading frames (ORFs) within the inserts and at their junctions, indicate that the expression of an ORF
showing signiﬁcant similarities to toxins or allergens is highly unlikely.8
Based on the above information, the EFSA GMO Panel considers that its previous conclusions on
the safety of the single maize events remain valid.
3.3. Risk assessment of the ﬁve-event stack maize Bt11 3 59122 3
MIR604 3 1507 3 GA21
3.3.1. Molecular characterisation
Possible interactions affecting the integrity of the single events, protein expression level or the
biological function conferred by the individual inserts are considered below.
Events Application or mandate EFSA Scientiﬁc Opinions
Bt11 9 GA21 EFSA-GMO-UK-2007-49 2009e
EFSA-GMO-DE-2009-66 2015a
Bt11 9 MIR604 EFSA-GMO-UK-2007-50 2010b
EFSA-GMO-DE-2009-66 2015a
Bt11 9 MIR604 9 GA21 EFSA-GMO-UK-2008-56 2010c
EFSA-GMO-DE-2009-66 2015a
EFSA GMO Panel: Panel on Genetically Modiﬁed Organisms of the European Food Safety Authority.
(a): Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2012-00713
5 Additional information: 21/7/2015, 24/9/2015.
6 EFSA-Q-2015-00473 and EFSA-Q-2015-00475.
7 Additional information: 30/7/2015.
8 Additional information: 30/7/2015, 17/12/2015 (spontaneous submission), 4/4/2016.
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3.3.1.1. Genetic elements and their biological function
Maize Bt11, 59122, MIR604, 1507 and GA21 are combined by conventional crossing to produce the
ﬁve-event stack maize Bt11 9 59122 9 MIR604 9 1507 9 GA21. The structures of the inserts
introduced into the ﬁve-event stack maize are described in detail in the respective EFSA scientiﬁc
opinions and no new genetic modiﬁcations were involved. Genetic elements in the expression cassettes
of the single events are summarised in Table 3.
Intended effects of the inserts in maize Bt11 9 59122 9 MIR604 9 1507 9 GA21 are summarised
in Table 4.
Based on the known biological function of the newly expressed proteins (Table 4), the only
foreseen interactions at the biological level are between the Cry proteins.
Table 3: Genetic elements in the expression cassettes of the events stacked in maize
Bt11 9 59122 9 MIR604 9 1507 9 GA21
Event Promoter 50 UTR Transit peptide Coding region Terminator
Bt11 35S (CaMV)* IVS6
(Zea mays)
No cry1Ab
(Bacillus thuringiensis)
nos (Agrobacterium
tumefaciens)
35S (CaMV) IVS2 (Z. mays) No pat (Streptomyces
viridochromogenes)
nos (A. tumefaciens)
59122 ubiZM1 (Z. mays) – No cry34Ab1
(B. thuringiensis)
pinII (Solanum
tuberosum)
Wheat peroxidase
(Triticum
aestivum)
– No cry35Ab1
(B. thuringiensis)
pinII
(S. tuberosum)
35S (CaMV) – No pat
(S. viridochromogenes)
35S (CaMV)
MIR604 MTL (Z. mays) – No mcry3A
(B. thuringiensis)
nos (A. tumefaciens)
ZmUbiInt
(Z. mays)
– No pmi
(Escherichia coli)
nos (A. tumefaciens)
1507(a) ubiZM1 (Z. mays) – No cry1F
(B. thuringiensis)
ORF25PolyA
(A. tumefaciens)
35S (CaMV) – No pat
(S. viridochromogenes)
35S (CaMV)
GA21 Actin 1
(Oryza sativa)
Actin 1
(O. sativa)
OTP
(Helianthus annuus)
mepsps (Z. mays) nos
(A. tumefaciens)
CaMV: cauliﬂower mosaic virus; UTR: untranslated region.
(*): Source of genetic information.
(–): When no element was speciﬁcally introduced to optimise expression.
(a): Maize 1507 also contains partial fragments of the cry1F and pat genes at a single locus in the nuclear genome.
Table 4: Characteristics and intended effects of the events stacked in maize Bt11 9 59122 9
MIR604 9 1507 9 GA21
Event Protein Donor organism and biological function Intended effects in GM plant
Bt11 Cry1Ab
PAT
Based on a gene from Bacillus thuringiensis
var. kurstaki HD-1. B. thuringiensis is an insect
pathogen; its insecticidal activity is attributed
to the expression of crystal protein (cry) genes
(Schnepf et al., 1998)
Based on a gene from Streptomyces viridochro-
mogenes strain T€u494. Phosphinothricin-
acetyltransferase (PAT) enzyme acetylates
L-glufosinate-ammonium and thereby confers
tolerance to phosphinothricin-based herbicides
(Wohlleben et al., 1988)
Event Bt11 expresses a truncated version
of the Cry1Ab protein. Cry1Ab is a protein
toxic to certain lepidopteran larvae feeding
on maize
Event Bt11 expresses a synthetic version
of the PAT protein, which confers
tolerance to glufosinate ammonium-based
herbicides
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3.3.1.2. Integrity of the events in the ﬁve-event stack maize Bt11 3 59122 3 MIR604 3
1507 3 GA219
The genetic stability of the inserted DNA over multiple generations in the ﬁve single maize events
was demonstrated previously (EFSA, 2004, 2005a, 2007b,c, 2009b). Integrity of these events was
demonstrated in the ﬁve-event stack maize by Southern analyses.10
3.3.1.3. Information on the expression of the inserts11
Plants were grown at a single location (ﬁve replicate blocks) under ﬁeld conditions in 2009 in the
USA. The levels of Cry1Ab, Cry34Ab1, Cry35Ab1, mCry3A, Cry1F, PAT, PMI and mEPSPS proteins in the
ﬁve-event stack maize and the ﬁve single events were quantiﬁed by enzyme-linked immunosorbent
Event Protein Donor organism and biological function Intended effects in GM plant
59122 Cry34Ab1
Cry35Ab1
PAT
Based on a gene from B. thuringiensis strain
PS149B1. B. thuringiensis is an insect
pathogen; its insecticidal activity is attributed
to the expression of crystal protein (cry) genes
(Schnepf et al., 1998; Ellis et al., 2002)
Based on a gene from B. thuringiensis strain
PS149B1. B. thuringiensis is an insect
pathogen; its insecticidal activity is attributed
to the expression of crystal protein (cry) genes
(Schnepf et al., 1998; Ellis et al., 2002)
Based on a gene from S. viridochromogenes.
PAT enzyme confers resistance to the antibiotic
bialaphos (Wohlleben et al., 1988)
Event 59122 expresses a cry34Ab1 gene
which was modiﬁed to enhance expression
in plants. The amino acid sequence was not
modiﬁed. Cry34Ab1 is a protein toxic to
certain coleopteran larvae feeding on maize
Event 59122 expresses a cry35Ab1 gene
which was modiﬁed to enhance expression
in plants. The amino acid sequence was not
modiﬁed. Cry35Ab1 is a protein toxic to
certain coleopteran larvae feeding on maize
PATacetylates L-glufosinate-ammonium
and thereby confers tolerance to
glufosinate ammonium-based herbicides
MIR604 mCry3A
PMI
Based on a gene from B. thuringiensis subsp.
tenebrionis (Sekar et al., 1987).
B. thuringiensis is an insect pathogen; its
insecticidal activity is attributed to the
expression of crystal protein (cry) genes
(Schnepf et al., 1998)
Based on a gene from Escherichia coli.
Phosphomannose isomerase (PMI) catalyses
the isomerisation of mannose-6-phosphate to
fructose-6-phosphate and plays a role in the
metabolism of mannose (Markovitz et al., 1967)
The N-terminal 48 amino acid residues of
the native Cry3A protein were deleted. In
addition, a cathepsin-G protease
recognition site was introduced for
enhanced efﬁciency towards target pests
(Chen and Stacy, 2003). Cry3A is a protein
toxic to certain coleopteran larvae feeding
on maize
PMI is used as a selectable marker in
maize MIR604. Mannose normally inhibits
root growth, respiration and germination.
Transformed cells expressing PMI are able
to utilise mannose as a carbon source
(Negrotto et al., 2000)
1507 Cry1F
PAT
Based on a gene from B. thuringiensis subsp.
aizawai. B. thuringiensis is an insect pathogen;
its insecticidal activity is attributed to the
expression of crystal protein (cry) genes
(Schnepf et al., 1998)
Based on a gene from S. viridochromogenes
strain T€u494. PAT enzyme confers resistance
to the antibiotic bialaphos (Wohlleben et al.,
1988)
Event 1507 expresses a synthetic version
of the truncated Cry1F protein. Cry1F is a
protein toxic to certain lepidopteran larvae
feeding on maize
Event 1507 expresses a synthetic version
of the PAT protein, which confers
tolerance to glufosinate ammonium-based
herbicides
GA21 mEPSPS Based on a gene from Zea mays
5-enolpyruvylshikimate-3-phosphate synthase
(EPSPS) is an enzyme involved in the shikimic
acid pathway for aromatic amino acid
biosynthesis in plants and microorganisms
(Herrmann, 1995)
The amino acid sequence of the maize
EPSPS enzyme was modiﬁed to render the
maize tolerant to glyphosate. Expression
of mEPSPS confers tolerance to
glyphosate-based herbicides (Lebrun
et al., 2003)
GM: genetically modiﬁed.
9 Dossier: Part I – Section D5.
10 Dossier: Part I – Section D5 and Appendix 3.
11 Dossier: Part I – Section D3.
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assay (ELISA). Protein levels were determined in leaves (V5 stage), root (R1 stage), pollen (R1 stage),
whole plant (R1 stage) and grain (R6 stage). Only data on grain at physiological maturity is reported
below (Table 5).
Interactions between events may result in changes of expression of the newly expressed proteins.
Cry1Ab, Cry34Ab1, Cry35Ab1, mCry3A, Cry1F, PAT, PMI and mEPSPS proteins in the ﬁve-event stack
maize were comparable to the corresponding levels in the single maize events and showed no changes
that could be the result of such interactions (see Table 5 for protein levels in grain).
3.3.1.4. Conclusion of the molecular characterisation
The molecular data establish that the events stacked in maize Bt11 9 59122 9 MIR604 9
1507 9 GA21 have retained their integrity. Protein expression analyses showed that the levels of the
newly expressed proteins are similar in the ﬁve-event stack and in the single events. Therefore, there
is no indication of an interaction that may affect the integrity of the events and the levels of the newly
expressed proteins in this stack.
Based on the known biological function of the newly expressed proteins, the only foreseen
interactions at the biological level are between the Cry proteins in susceptible insects, which will be
dealt with in Section 3.3.4.
3.3.2. Comparative assessment
3.3.2.1. Choice of comparator and production of material for the comparative
assessment12
Two comparative ﬁeld studies were performed, one for agronomic and phenotypic characterisation
and one for compositional analysis.
For the analysis of agronomic and phenotypic characteristics, the ﬁve-event stack maize and its
conventional counterpart were grown in 11 locations in the USA in 2009.
The conventional counterpart in these ﬁeld trials was a non-GM maize line (5XH751/NP2222) with a
genetic background comparable with that of maize Bt11 9 59122 9 MIR604 9 1507 9 GA21 (as
documented by the pedigree). At each location, the test materials were grown according to a
randomised complete block design with four replicates. A maintenance pesticide treatment was applied
to all maize materials according to the need at each site. No treatments of the ﬁve-event stack maize
Table 5: Means (upper row) and ranges (lower row) of protein levels (lg/g dry weight) in grain at
physiological maturity from the single maize events Bt11, 59122, MIR604, 1507, GA21 and the ﬁve-
event stack maize
Protein
Bt11 3 59122 3 MIR604 3
1507 3 GA21
Bt11 59122 MIR604 1507 GA21
Cry1Ab 2.08
1.64–2.64
2.17
1.58–2.86
– – – –
Cry34Ab1 80.83
56.2–133.4
– 92.25
59.6–158.2
– – –
Cry35Ab1 1.82
1.55–2.06
– 2.02
1.80–2.57
– – –
mCry3A 0.42
0.34–0.50
– – 0.42
0.35–0.57
– –
Cry1F 2.63
1.99–3.34
– – – 2.74
2.23–3.75
–
PAT 0.12
0.06–0.17
LOQ LOQ–0.09 – LOQ –
PMI 2.57
2.11–2.93
– – 2.80
2.46–3.78
– –
mEPSPS 11.88
8.97–13.28
– – – – 10.89
9.15–13.27
LOQ: values below limit of quantiﬁcation.
–: not assayed.
12 Dossier: Part I – Section D7.2.
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with the intended herbicides were included in the study. This experimental design allows a direct
comparison between the ﬁve-event stack maize and its conventional counterpart in the absence of
target herbicides.
For the compositional analysis of forage and grain, a set of ﬁeld trials was performed in six
locations in the USA in 2009. At each location, the following test materials (all treated with
maintenance pesticides) were grown in a randomised complete block design with four replicates: the
ﬁve-event stack maize, its conventional counterpart (maize 5XH751/NP2222) and the ﬁve-event stack
maize additionally treated with glyphosate- and glufosinate-ammonium-based herbicides.
Additionally, in a separate ﬁeld trials study,13 eight non-GM commercially available maize lines were
grown at eight sites in the USA in 200914 (in a randomised complete block design with four replicates),
in order to establish the range of natural variation for maize compositional parameters.
Data on compositional and agronomic and phenotypic endpoints were statistically analysed for
potential differences between maize Bt11 9 59122 9 MIR604 9 1507 9 GA21 and its conventional
counterpart using the two analysis of variance (ANOVA) models: an across-site analysis (all trial sites
combined) and an individual-site analysis.15 Summary statistics of compositional data for the non-GM
commercial reference varieties13 were used for comparison, with no formal analysis.
3.3.2.2. Agronomic and phenotypic analysis16
The analysis of agronomic and phenotypic characteristics included 14 endpoints related to crop
physiology, morphology, development and yield. Data collected for seven of the 14 endpoints were
subject to ANOVA.17 For the other seven endpoints, which couldn’t be analysed by ANOVA, only
summary statistics were provided.18
In the across-site analysis, signiﬁcant differences between the ﬁve-event stack maize and its
conventional counterpart were identiﬁed for early and ﬁnal stand count. The mean early stand count
(plants per plot) was 73.4 and 77.1 for maize Bt11 9 59122 9 MIR604 9 1507 9 GA21 and the
conventional counterpart, respectively; the mean ﬁnal stand count (plants per plot) was 71.4 and 74.9
for maize Bt11 9 59122 9 MIR604 9 1507 9 GA21 and the conventional counterpart, respectively.
The differences in agronomic characteristics are further assessed for their potential environmental
impact in Section 3.3.4.
3.3.2.3. Compositional analysis19
The compositional analysis included 59 compositional parameters for grain20 and nine for forage,21
consistently with OECD recommendations (OECD, 2002).
Table 6 shows the results for the forage and grain parameters for which signiﬁcant differences were
found between maize Bt11 9 59122 9 MIR604 9 1507 9 GA21 and its conventional counterpart. For
forage composition, a statistically signiﬁcant difference for phosphorus was observed between maize
Bt11 9 59122 9 MIR604 9 1507 9 GA21 (both treated and not treated with the target herbicides)
and the conventional counterpart. For grain components, 16 signiﬁcant differences with respect to the
conventional counterpart were found for maize Bt11 9 59122 9 MIR604 9 1507 9 GA21 (untreated)
and 15 statistically signiﬁcant differences for maize Bt11 9 59122 9 MIR604 9 1507 9 GA21 (treated
with target herbicides). Thirteen of the signiﬁcant differences were common to both treatments.
13 Additional information 28/7/2014/Appendix 16.
14 York, NB; Swanton, OH; Deerﬁeld, MI; Richland, IO; Seymour, IL; York, NB; Kimballton, IO; Elk Horn, IO.
15 In both models, the overall mean and the genotype effect were ﬁxed factors. The random factors were: the block effect for
the individual-site analysis and the site effect, block-within-site effect and site-by-genotype interaction for the across-site
analysis.
16 Dossier: Part I – Section D7.4.
17 The following endpoints were analysed: early stand count, ear height, plant height, ﬁnal stand count, grain yield, grain
moisture and test weight.
18 The endpoints were early growth rating, days to 50% pollen shed, days to 50% silking, stay green, root lodged plants, stalk
lodged plants and dropped ears.
19 Dossier: Part I – Section D7.3.
20 Moisture, protein, fat, ash, carbohydrates by calculation, acid detergent ﬁbre (ADF), neutral detergent ﬁbre (NDF), total
dietary ﬁbre (TDF), starch, calcium, copper, iron, magnesium, manganese, phosphorus, potassium, selenium, sodium, zinc,
b-carotene, thiamine, riboﬂavin, niacin, pyridoxine, folic acid, a-tocopherol, alanine, arginine, aspartic acid, cysteine, glutamic
acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine,
valine, 16:0 palmitic acid, 18:0 stearic acid, 18:1 oleic acid, 18:2 linoleic acid, 18:3 linolenic acid, 20:0 arachidic acid, 20:1
eicosenoic acid, 22:0 behenic acid, ferulic acid, furfural, inositol, p-coumaric acid, phytic acid, rafﬁnose and trypsin inhibitor.
21 Proximates (moisture, crude protein, crude fat and carbohydrates by calculation), starch, ﬁbre (ADF and NDF) and minerals
(calcium and phosphorus).
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The levels of carbohydrates, copper, potassium, niacin and inositol in maize Bt11 9 59122 9
MIR604 9 1507 9 GA21 (treated and untreated) fell within the range of variation established by the
non-GM commercial maize varieties in the US 2009 ﬁeld trials.13
For the remaining endpoints in Table 6, which fell outside the range of the commercial varieties,
the EFSA GMO Panel considered the magnitude of the observed levels and the well-known biochemical
roles and characteristics of the parameters, and concluded that further assessment for potential
impacts on human and animal health was not required.
3.3.2.4. Conclusion
The EFSA GMO Panel concludes that none of the observed differences in the agronomic, phenotypic
and compositional characteristics of grain and forage identiﬁed between maize Bt11 9 59122
9 MIR604 9 1507 9 GA21 and its conventional counterpart requires further assessment regarding
food and feed safety.
The differences in agronomic and phenotypic characteristics are further assessed for their potential
environmental impact in Section 3.3.4.
Table 6: Compositional endpoints (US 2009 ﬁeld trials data) for which signiﬁcant differences were
found between maize Bt11 9 59122 9 MIR604 9 1507 9 GA21 and its conventional
counterpart 5XH751/NP2222. For the GM maize, the conventional counterpart and the
non-GM commercial varieties, the values shown are estimated means and signiﬁcantly
different entries are marked with an asterisk. For the non-GM commercial varieties, the
range of mean values (averaged across sites) is shown
Endpoint
Conventional
counterpart
(5XH751/NP2222)(a)
Maize
Bt11 3 591223 MIR604 3
1507 3 GA21
Non-GM maize
commercial
varieties(a),(c)
Untreated(a) Treated(b)
Forage
Phosphorus (mg/kg dw) 1,812 2,002* 2,048* 1,763–2,034
Grain(a)
Fat (% dw) 4.21 4.39* 4.36* 3.32–4.15
Carbohydrates (% dw) 84.9 84.3* 84.2* 83.6–86.1
Copper (mg/kg dw) 1.82 1.64* 1.66* 1.61–2.22
Phosphorus (mg/kg dw) 2,957 3,243* 3,304* 2,766–3,105
Potassium (mg/kg dw) 3,752 3,960* 4,041* 3,367–4,188
Zinc (mg/kg dw) 20.5 19.1* 19.5* 20.4–25.1
b-carotene (mg/kg dw) 0.776 0.721* 0.749 1.14–1.85
Thiamine (mg/kg dw) 2.85 2.98* 2.96* 3.13–4.01
Niacin (mg/kg dw) 25.2 23.6* 23.6* 17.8–26.6
Pyridoxine (mg/kg dw) 5.15 4.56* 4.52* 4.80–7.03
Oleic acid (18:1) (% FA) 28.5 28.0 27.7* 22.0–27.2
Linoleic acid (18:2) (% FA) 53.4 53.9* 54.1* 54.9–61.4
Arachidic acid (20:0) (% FA) 0.430 0.424* 0.424* 0.377–0.408
Eicosenoic acid (20:1) (% FA) 0.249 0.240* 0.239* 0.252–0.309
Ferulic acid (mg/kg dw) 2,752 2,584* 2,627* 1,650–2,420
Inositol (lg/g dw) 2,425 2,603* 2,557 2,417–2,682
Phytic acid (% dw) 0.819 0.907* 0.890* 0.781–0.893
DW: dry weight; % FA: percentage of total fatty acids.
(a): Not treated with the target herbicides.
(b): Treated with the target herbicides.
(c): Additional information 28/7/2014/Appendix 16.
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3.3.3. Food and feed safety assessment
3.3.3.1. Effect of processing22
Based on the outcome of the comparative assessment, processing of the ﬁve-event stack maize
Bt11 9 59122 9 MIR604 9 1507 9 GA21 into food and feed products is not expected to result in
products different from those of commercial non-GM maize varieties.
3.3.3.2. Toxicology
Toxicological assessment of newly expressed proteins
Eight proteins are newly expressed in the ﬁve-event stack maize (Section 3.3.1.3). The EFSA GMO
Panel has previously assessed these proteins individually in the context of the single events, and no
safety concerns were identiﬁed.
The three enzymatic proteins (PAT, PMI and mEPSPS) act on unrelated substrates and are not
expected to interact. The ﬁve insecticidal proteins (Cry1Ab, Cry34Ab1 and Cry35Ab1, mCry3A, Cry1F)
act through cellular receptors found in target insect species. It is reported that the gastrointestinal
tract of mammals, including humans, lacks receptors with high speciﬁc afﬁnity to Cry proteins
(Hammond et al., 2013; Koch et al., 2015).
On the basis of the known biological function of the individual newly expressed proteins (Table 4),
there is currently no expectation for possible interactions relevant to the food and feed safety
assessment of the ﬁve-event stack maize Bt11 9 59122 9 MIR604 9 1507 9 GA21.
The EFSA GMO Panel concludes that there are no safety concerns to human and animal health
related to the newly expressed proteins Cry1Ab, Cry34Ab1 and Cry35Ab1, mCry3A, Cry1F, PAT, PMI
and mEPSPS in the ﬁve-event stack maize Bt11 9 59122 9 MIR604 9 1507 9 GA21.
Toxicological assessment of components other than newly expressed proteins
The ﬁve-event stack maize does not show any compositional difference to its conventional
counterpart that would require further assessment (see Section 3.3.2.3).
3.3.3.3. Animal studies with the food/feed derived from GM plants
None of the observed differences in the composition of the food/feed derived from maize
Bt11 9 59122 9 MIR604 9 TC1507 9 GA21 (see Section 3.3.2.3) require further assessment
regarding food and feed safety. Therefore, according to EFSA (EFSA GMO Panel, 2011), no animal
studies on the food/feed derived from maize Bt11 9 59122 9 MIR604 9 1507 9 GA21 are required.
However, the applicant provided a broiler study which was considered by the EFSA GMO Panel.
A 50-day feeding study with a total of 540 (half male and half female) cross-line chickens for
fattening (Ross 344-males 9 Ross 708-females) was performed.23 The birds were randomly allocated
to three dietary groups with 180 chicks per treatment (12 pens per treatment, 15 birds per pen, half
for each sex24). Because of water supply problems two pens were excluded from the study. Birds were
fed diets containing maize Bt11 9 59122 9 MIR604 9 1507 9 GA21 (identity veriﬁed by polymerase
chain reaction (PCR)), containing near-isogenic maize or one non-GM commercial variety (NCSU
200925). The starter (1–15 days), grower (16–34 days) and ﬁnisher GM diets consisted of 53.81%,
58.51% and 63.61% maize grain, respectively.26 Before feed formulation, all maize varieties were
analysed for proximates, amino acids and mycotoxins. The metabolisable energy was calculated for
each maize grain source. All diets were balanced for metabolisable energy, crude protein and amino
acids. Pelleted diets (starter crumbled) and water were offered ad libitum. The concentration of
proteins Cry1Ab, Cry34Ab1, Cry35Ab1, mCry3A, PMI, Cry1F and mEPSPS were determined analytically
in maize grain and the poultry diets prepared with this grain. Chickens were observed twice daily for
clinical signs, injuries and mortalities; deaths were recorded. Mean body weights and feed intake were
measured per pen at day 1, 16, 34 and 48. At the end of the study, two birds per pen were randomly
selected and processed in order to determine carcass (meat) yield. Body weight, feed intake, feed
conversion ratio and mortality data were statistically analysed using a two-way ANOVA (dietary
22 Dossier: Part I – Section D7.6.
23 Dossier: Part I – Section D7.8.4 and Appendix 28.
24 In the ﬁnal design, there were ﬁve pens and 75 birds per sex per transgenic treatment, due to a water pressure problem
which resulted in the loss of two pens, each containing 15 birds, one pen per sex on this treatment.
25 Commercially available, locally grown lot of North Carolina (NC, USA) maize grain from the 2009 season.
26 Near-isogenic diets (54.20%, 58.47% and 62.93%) and non-GM commercial variety diets (53.49%, 56.95% and 62.12%).
Opinion on GM maize Bt113 591223MIR6043 15073 GA21 and its subcombinations
www.efsa.europa.eu/efsajournal 15 EFSA Journal 2016;14(8):4567
group 9 sex), to determine statistical differences among groups fed diets prepared from the three
maize grain sources, and between males and females. Carcass data were analysed for effects due to
maize grain source within sex using a one-way ANOVA. Upon EFSA request, an additional statistical
analysis was conducted, wherein a direct comparison was made between the Bt11 9 59122 9
MIR604 9 TC1507 9 GA21 feeding group and the non-GM, near-isogenic control. Overall mortality
was low (< 2%) with no signiﬁcant difference between the groups.
No signiﬁcant interactions (diet 9 sex) were detected for body weights, feed intake and feed
conversion ratio at any time. No statistically signiﬁcant differences in body weight between dietary
groups were found at any time. No statistically signiﬁcant differences were observed in feed intake of
starter, grower nor ﬁnisher in broilers fed the GM diet and the non-GM diets. Considering feed intake in
the entire period (0–48 days), lower consumption in broilers fed the GM diet was identiﬁed as
compared to those fed non-GM diets. Higher moisture content in GM diet might contribute to this
difference. There were no statistically signiﬁcant differences in the carcass portions in both sexes
considered relevant by the EFSA GMO Panel. All above mentioned endpoints obtained from the two
groups (Bt11 9 59122 9 MIR604 9 TC1507 9 GA21 transgenic treatment and the non-transgenic,
near-isogenic control) were also subjected to the additional statistical analysis requested by EFSA
which results were in agreement with previous ones.
The EFSA GMO Panel concluded that this study did not detect unintended effects, and showed that
the ﬁve-event stack maize is as nutritious as its conventional counterpart and the non-GM commercial
variety tested in this study.
3.3.3.4. Allergenicity
For the allergenicity assessment, a weight-of-evidence approach was followed, taking into account
all of the information obtained on the newly expressed proteins, as no single piece of information or
experimental method yields sufﬁcient evidence to predict allergenicity (EFSA, 2006a; Codex
Alimentarius, 2009). In addition, when known functional aspects of the newly expressed protein or
structural similarity to known adjuvants may indicate an adjuvant activity, the possible role of these
proteins as adjuvants is considered. When newly expressed proteins with a potential adjuvant activity
are expressed together, possible interactions increasing adjuvanticity and impacting the allergenicity of
the GM crop are assessed.
Assessment of allergenicity of the newly expressed proteins27
For allergenicity, the EFSA GMO Panel has previously evaluated the safety of the Cry1Ab, mCry3A,
Cry34Ab1, Cry35Ab1, Cry1F, PAT, mEPSPS and PMI proteins individually, and no concerns on
allergenicity were identiﬁed in the context of the applications assessed (see EFSA scientiﬁc opinions
listed in Table 2). No new information on allergenicity of these proteins that might change the previous
conclusions of the EFSA GMO Panel has become available. Based on the current knowledge, and as
none of the newly expressed proteins showed allergenicity, no reasons for concerns regarding the
simultaneous presence of these newly expressed proteins in this ﬁve-event stack maize affecting
allergenicity were identiﬁed.
For adjuvanticity, proteins derived from B. thuringiensis (Bt proteins) have been suggested to
possess adjuvant activity based on animal studies on Cry1Ac when applied at relatively high doses
(e.g. Vazquez et al., 1999). The Panel has previously evaluated the safety of the Cry1Ab, mCry3A,
Cry34Ab1, Cry35Ab1 and Cry1F proteins and no concerns on adjuvanticity in the context of the
applications assessed were identiﬁed (see EFSA scientiﬁc opinions listed in Table 2). The levels of Bt
proteins in this ﬁve-event stack maize are similar to those in the respective single maize events (see
Table 5). From the limited experimental evidence available, the GMO Panel did not ﬁnd indications that
the presence of the Bt proteins at the levels expressed in this ﬁve-event stack maize might act as
adjuvants with the potential to enhance a speciﬁc immunoglobulin E (IgE) response and to favour the
development of an allergic reaction.
27 Dossier: Part I – Section D7.9.1 and additional information: 3/5/2013, 30/7/2015, 17/12/2015 (spontaneous submission),
4/4/2016 (updated bioinformatics).
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Assessment of allergenicity of GM plant products28
The EFSA GMO Panel regularly reviews the available publications on food allergy to maize (EFSA
GMO Panel, 2013). However, to date, maize has not been considered to be a common allergenic
food29 (OECD, 2002). Therefore, the EFSA GMO Panel did not request experimental data to analyse
the allergen repertoire of GM maize.
In the context of this application and considering the data from the molecular characterisation, the
compositional analysis and the assessment of the newly expressed proteins (see Sections 3.3.1 and
3.3.2.3), the EFSA GMO Panel identiﬁed no indications of a potentially increased allergenicity of food
and feed derived from the ﬁve-event stack maize with respect to that derived from its conventional
counterpart.
3.3.3.5. Nutritional assessment of GM food/feed30
The intended traits of maize Bt11 9 59122 9 MIR604 9 1507 9 GA21 are herbicide tolerance and
insecticide resistance, with no intention to alter the nutritional parameters. Comparison of the
composition of the ﬁve-event stack maize Bt11 9 59122 9 MIR604 9 1507 9 GA21 with its
conventional counterpart did not identify differences that would require a nutritional assessment as
regards to food and feed (see Section 3.3.2.3). From these data, the nutritional characteristics of the
ﬁve-event stack maize Bt11 9 59122 9 MIR604 9 1507 9 GA21 -derived food and feed are not
expected to differ from those of conventional counterpart. This conclusion is also supported by the
50-day feeding study with chickens for fattening (Section 3.3.3.3).
3.3.3.6. Conclusion
The newly expressed proteins in the ﬁve-event stack maize do not raise safety concerns for human
and animal health. No interactions between these proteins relevant for food and feed safety were
identiﬁed. Similarly, the EFSA GMO Panel did not identify indications of safety concerns regarding
allergenicity or adjuvanticity with the presence of newly expressed proteins in this ﬁve-event stack
maize, or regarding the overall allergenicity of the ﬁve-event stack maize. The ﬁve-event stack maize is
as nutritious as its conventional counterpart and the non-GM commercial variety used.
3.3.4. Environmental risk assessment31
The approach followed by the GMO Panel to assess environmental risks is to consider the scope of
the ﬁve-event stack maize, the modes of action of the introduced traits, the possible interactions and
the outcomes of the molecular characterization, as well as of the comparative analysis.
Considering the scope (which excludes cultivation) of the ﬁve-event stack maize, the environmental
risk assessment (ERA) is mainly concerned with (i) exposure of bacteria to recombinant DNA in the
gastrointestinal tract of animal fed GM material and bacteria present in environments exposed to faecal
material; and (ii) accidental release into the environment of viable grains of the ﬁve-event stack maize
during transportation and processing.
3.3.4.1. Persistence and invasiveness of the GM plant32
Maize is highly domesticated, not winter hardy in colder regions of Europe, and generally unable to
survive in the environment without appropriate management. Occasional maize plants may occur
outside cultivation areas but survival is limited mainly by a combination of low competitiveness, the
absence of a dormancy phase and susceptibility to plant pathogens, herbivores and cold climate
conditions (OECD, 2002). In ﬁelds, maize volunteers may arise under some environmental conditions
(mild winters). Observations done in the ﬁeld during harvesting indicate that grain may survive and
overwinter in some regions, resulting in volunteers in subsequent crops. The occurrence of maize
volunteers has been reported in Spain and other European regions (e.g. Gruber et al., 2008). However,
maize volunteers have been shown to grow weakly and ﬂower asynchronously with the maize crop
(Palaudelmas et al., 2009).
28 Dossier: Part I – Section D7.9.2.
29 Directive 2007/68/EC of the European Parliament and of the Council of 27 November 2007 amending Annex IIIa to Directive
2000/13/EC of the European Parliament and of the Council as regards certain food ingredients. OJ L 310, 27.11.2007, p. 11–14.
30 Dossier: Part I – Section D7.10.
31 Dossier: Part I – Section D9.
32 Dossier: Part I – Section D9.1 and D9.2.
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As mentioned in Section 3.3.2.1, a ﬁeld trials study was carried out in the USA in 2009 to assess
the agronomic and phenotypic performance33 of the ﬁve-event stack maize in comparison with its
conventional counterpart. Signiﬁcantly different values were observed for two characteristics of the
ﬁve-event stack maize, i.e. initial and ﬁnal stand count. In both cases, the ﬁve-event stack maize
showed a lower number of plants per plot (see Section 3.3.2.2). Due to the lack of seed germination
studies, it was not possible to assess if the observed differences were related to a different
germination capacity of the starting materials. A reduction in early stand count was also identiﬁed in
the agronomic and phenotypic ﬁeld trials performed during the comparative assessment of two events
of the ﬁve-event stack maize, namely maize 59122 and GA21 (EFSA, 2007b; EFSA GMO Panel, 2013).
The differences observed suggested a lower ﬁtness of the ﬁve-event stack maize than that of its
conventional counterpart (i.e. underperforming compared to its conventional counterpart). As no
statistically signiﬁcant differences were observed for the other assessed agronomic and phenotypic
characteristics which may affect ﬁtness characteristics of the ﬁve-event stack maize, the EFSA GMO
Panel considers that these differences do not induce a change in the persistence and invasiveness of
the ﬁve-event stack maize compared to conventional maize.
In addition to the data presented by the applicant, the EFSA GMO Panel is not aware of any
scientiﬁc report of increased spread, establishment and survival capacity of the ﬁve-event stack maize
or maize with comparable properties.
Therefore, the EFSA GMO Panel concludes that it is unlikely that the ﬁve-event stack maize would
differ from conventional maize varieties in its ability to survive until subsequent season under European
environmental conditions, if there was accidental release of viable GM maize grains into the
environment. The occurrence of GM maize plants in the environment will thus be limited.
3.3.4.2. Gene transfer34
A prerequisite for any gene transfer is the availability of pathways for the transfer of genetic
material, either through horizontal gene transfer of DNA or through vertical gene ﬂow by cross-
pollination from ﬂowering plants arising from spilled grains.
Plant-to-microorganism gene transfer
The potential for horizontal gene transfer of the recombinant DNA of the ﬁve single events to
bacteria was assessed in previous opinions (see EFSA scientiﬁc opinions listed in Table 2). No concern
for an unlikely, but theoretically possible, horizontal gene transfer of the recombinant genes to bacteria
in the gut of animal fed GM material or other receiving environments was identiﬁed. Synergistic effects
of the recombinant genes in increasing the likelihood for horizontal gene transfer, for instance
combinations of recombinogenic sequences, were not identiﬁed. Therefore, the EFSA GMO
Panel concludes that, in the context of its scope, the unlikely, but theoretically possible, horizontal
transfer of recombinant genes from this ﬁve-event stack maize to bacteria does not raise any
environmental safety concern.
Plant-to-plant gene transfer
Considering the scope of the ﬁve-event stack maize and the biology of maize, a possible pathway
to harm pertains to the potential of occasional feral GM maize plants originating from accidental
spillage of imported grains to transfer recombinant DNA to sexually cross-compatible plants. As
pointed out above (Section 3.3.4.1), occurrence of feral GM maize is expected to be limited.
The extent of cross-pollination to other maize varieties will mainly depend on the scale of accidental
release during transportation and processing and on successful establishment and subsequent
ﬂowering of the GM maize plant. For maize, vertical gene transfer is limited to other Zea species.
Populations of sexually compatible indigenous wild relatives of maize are not known in Europe
(Eastham and Sweet, 2002; OECD, 2003), therefore vertical gene transfer is not considered to be an
environmental issue in the EU.
The ﬂowering of occasional feral GM maize plants originating from accidental release during
transportation and processing is unlikely to lead to dispersal of signiﬁcant amounts of GM maize pollen
onto other maize plants. Field observations performed on maize volunteers after GM maize cultivation
in Spain revealed that maize volunteers had a low vigour, rarely had cobs and produced pollen that
cross-pollinated neighbouring plants only at low levels (Palaudelmas et al., 2009). Thus, the likelihood
33 Dossier: Part I – Section D7.1/Appendix 14/Additional information on 3/5/2013.
34 Dossier: Part I – Section D9.3.
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of cross-pollination between cultivated maize and the occasional feral maize plants resulting from grain
spillage is considered extremely low.
In conclusion, the EFSA GMO Panel is of the opinion that the likelihood of spread of genes from this
GM maize in Europe will not differ from that of conventional maize varieties, even in the case of
treatment with the intended herbicides.
3.3.4.3. Interactions of the GM plant with target organisms35
Interactions might occur between different Cry proteins depending on the arthropod species tested
(EcoƩtat, 2014; De Schrijver et al., 2015). Considering the scope of application EFSA-GMO-DE-2011-99,
and the low level of exposure of the environment to this GM maize, interactions of the GM seeds or
plants arising from spilled grains with target organisms are not considered a relevant issue by the EFSA
GMO Panel, regardless of potential synergistic interactions that might occur between the different Cry
proteins.
3.3.4.4. Interactions of the GM plant with non-target organisms36
The EFSA GMO Panel has previously assessed the Cry1Ab, Cry1F, Cry34Ab1, Cry35Ab1 and mCry3
proteins individually in the context of the single maize events, and no safety concern was identiﬁed for
non-target organisms. As mentioned in Section 3.3.4.3, interactions between Cry proteins, leading to
synergistic insecticidal effects, might occur in other susceptible non-target species. Considering that
environmental exposure of non-target organisms to stored GM grains, spilled GM grains or GM plants
arising from spilled GM grains is limited, potential exposure of non-target organisms sensitive to either
combination of the Cry1Ab, Cry1F Cry34Ab1, Cry35Ab1 or mCry3 proteins is likely to be very low and
of no biological relevance.
The EFSA GMO Panel evaluated whether the Cry1Ab, Cry1F, Cry34Ab1, Cry35Ab1 and mCry3
proteins might potentially affect non-target organisms by entering the environment through faecal
material of animals fed the ﬁve-event stack maize. Cry proteins are degraded by enzymatic activity in
the gastrointestinal tract, meaning that only a very low amount of these proteins would remain intact
to pass out in faeces. This was demonstrated for Cry1Ab (Einspanier et al., 2004; Lutz et al., 2005,
2006; Wiedemann et al., 2006; Guertler et al., 2008; Paul et al., 2010). Further degradation of the
protein in the manure and faeces would take place because of microbiological proteolytic activity. In
addition, there will be further degradation of the Cry proteins in soil reducing the possibility for
exposure of potentially sensitive non-target organisms. While proteins, including insecticidal Cry
proteins, may bind to clay minerals and organic substances in soil, thereby reducing their availability to
microorganisms for degradation, there are no indications of persistence and accumulation of these
proteins from GM crops in soil (Gruber et al., 2012; Valldor et al., 2015). The EFSA GMO Panel is not
aware of evidence of released Bt proteins causing signiﬁcant negative effects on soil microorganisms.
Considering the scope of the ﬁve-event stack maize, it can be concluded that the exposure of
potentially sensitive non-target organisms to the Cry1Ab, Cry1F, Cry34Ab1, Cry35Ab1 and mCry3
proteins expressed in the ﬁve-event stack maize is likely to be very low and of no biological relevance,
regardless of potential synergistic interactions that might occur between the different Cry proteins.
3.3.4.5. Interactions with the abiotic environment and biogeochemical cycles37
Considering the scope of the ﬁve-event stack maize and the low level of exposure to the
environment, potential interactions with the abiotic environment and biogeochemical cycles were not
considered a relevant issue by the EFSA GMO Panel.
3.3.4.6. Conclusion
The EFSA GMO Panel concludes that it is unlikely that the ﬁve-event stack maize would differ from
conventional maize varieties in its ability to survive until subsequent seasons under the European
environmental conditions. Considering the scope of the GM maize, interactions with the biotic and
abiotic environment were not considered to be a relevant issue. Risks associated with an unlikely but
theoretically possible horizontal gene transfer of recombinant DNA from the ﬁve-event stack maize to
bacteria have not been identiﬁed.
35 Dossier: Part I – Section D9.4.
36 Dossier: Part I – Section D9.5.
37 Dossier: Part I – Section D9.8 and D9.10.
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Therefore, considering the combined traits and their potential interactions, the outcome of the
comparative analysis, the route of exposure and the exposure levels, the EFSA GMO Panel concluded
that this ﬁve-event stack maize would not raise safety concerns in the event of accidental release of
viable GM maize grains into the environment.
3.3.5. Conclusion on the ﬁve-event stack maize Bt11 3 59122 3 MIR604 3
1507 3 GA21
The combination of maize events Bt11, 59122, MIR604, 1507 and GA21 in the ﬁve-event stack
maize does not raise issues relating to molecular, agronomic, phenotypic or compositional
characteristics that would require further investigations.
The newly expressed proteins in the ﬁve-event stack maize do not raise safety concerns for human
and animal health and the environment in light of the scope of this application.
No indications of interactions between the events based on the biological functions of the newly
expressed proteins that would raise a safety issue were identiﬁed. Comparison of the levels of the
newly expressed proteins between the ﬁve-event stack and each of the single events did not reveal an
interaction that manifests at protein expression level.
Considering the introduced traits and the outcome of the comparative analysis, the routes of
exposure and limited environmental exposure levels, the EFSA GMO Panel concludes that the ﬁve-
event stack maize would not raise safety concerns in the event of accidental release of viable GM
maize seeds into the environment.
3.4. Risk assessment of the subcombinations
All 20 subcombinations included in the scope of this application as listed in Table 1 were not
previously assessed by the EFSA GMO Panel and no speciﬁc data were available for any of them.
The risk assessment of the 20 subcombinations covered by the scope followed a weight-of-evidence
approach that takes as a starting point results of the assessment of the single events, the data
generated for the ﬁve-event stack maize, and all the data available for subcombinations previously
assessed (2009b, 2009e, 2010a, 2010b, 2010c, 2015a) but not included in the scope.
The EFSA GMO Panel assessed to what extent a combination of any of these events resulting in
stacks with fewer than ﬁve events (see Table 1) could result in interactions manifesting at protein or
trait expression level not observed in the ﬁve-event stack (e.g. because of masking). The potential for
such interactions was addressed by investigating the known biological functions of the newly
expressed proteins, and the new data submitted.
Integrity of the inserts was demonstrated in the ﬁve-event stack (see Section 3.3.1.2). The EFSA
GMO Panel ﬁnds no reasons to expect the loss of integrity in any of the other subcombinations that
would result from interactions between the events.
The Cry1Ab, Cry34Ab1, Cry35Ab1, mCry3A, Cry1F, PAT, PMI and mEPSPS proteins levels in the ﬁve-
event stack maize were comparable to the corresponding levels in the single maize events and showed
no major changes that could be the result of interactions (see Section 3.3.1.3).
No indication of interactions between the events based on biological functions of the newly
expressed proteins that would raise a safety issue was identiﬁed in the ﬁve-event stack maize. In
addition, the data on genetic stability and protein expression from the previously assessed ﬁve
subcombinations (Table 2) do not show any evidence of interactions. Therefore, there is no indication
to suggest that the presence of one protein may mask or enhance the effects of the others and there
is no reason to expect interactions that would alter the expression levels of these proteins in the 20
subcombinations included in the scope of this application. However, at relatively high doses, the Bt
proteins might act as adjuvants (see Section 3.3.3.4). Given the anticipated expression levels in the
subcombinations that are similar to those measured in the singles, the ﬁve-event stack and the
subcombinations already assessed (EFSA, 2005a, 2009b, 2009e, 2010a, 2010b; EFSA GMO Panel,
2015a), this scenario is considered extremely unlikely. However, to mitigate uncertainty, the EFSA GMO
Panel has included a recommendation that, if any of the subcombinations were to be created via
targeted breeding approaches and commercialised in the future, the applicant should provide relevant
information including expression levels of the newly expressed proteins.
It is not expected that any combination of the newly expressed proteins would impact on the gross
composition and consequently the nutritional characteristics of the maize variety into which they may
be introduced. This was shown by the comparative analyses of the ﬁve-event stack maize and
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conﬁrmed by the comparative analyses of ﬁve subcombinations with their conventional counterparts
(EFSA, 2004, 2005a, 2007b,c, 2009a, 2009d).
Considering the scope of the application, the mode of action of the introduced traits, the data
available for various stacks and the poor ability of maize to survive outside cultivated land, the EFSA
GMO Panel is of the opinion that different combinations of these events would not raise environmental
concerns.
The 20 subcombinations included in the scope of this application are expected to be as safe as the
ﬁve-event stack maize.
3.5. Post-market monitoring
3.5.1. Post-market monitoring of GM food/feed38
The EFSA GMO Panel considers that post-market monitoring of GM food/feed is not necessary,
given the absence of safety concerns identiﬁed for the ﬁve-event stack maize and the 20 lower
subcombinations. If these subcombinations were to be created via targeted breeding approaches and
imported into the EU, the requirement for monitoring should be considered on the basis of new data
provided.
3.5.2. Post-market environmental monitoring39
The objectives of a PMEM plan according to Annex VII of Directive 2001/18/EC are: (1) to conﬁrm
that any assumption regarding the occurrence and impact of potential adverse effects of the GMO, or
its use, in the ERA are correct and (2) to identify the occurrence of adverse effects of the GMO, or its
use, on human health or the environment which were not anticipated in the ERA.
Monitoring is also related to risk management, and thus a ﬁnal adoption of the PMEM plan falls
outside the mandate of the EFSA GMO Panel. However, the EFSA GMO Panel gives its opinion on the
scientiﬁc quality of the PMEM plan provided by the applicant (EFSA, 2011a).
As the ERA did not identify potential adverse environmental effects due to the ﬁve-event stack
maize (Section 3.3.4), no case-speciﬁc monitoring is required.
The PMEM plans proposed by the applicant for the ﬁve-event stack maize and for the 20
subcombinations covered by the scope of application EFSA-GMO-DE-2011-99 includes (1) the
description of a monitoring approach involving operators (federations involved in maize import and
processing), reporting to applicants, via a centralised system, any observed adverse effect(s) of GMOs
on human health and the environment; (2) a coordinating system established by EuropaBio for the
collection of the information recorded by the various operators; and (3) the use of networks of existing
surveillance systems (Lecoq et al., 2007; Windels et al., 2008). The applicant proposes to submit a
PMEM report on an annual basis.
The EFSA GMO Panel is of the opinion that the PMEM plan proposed by the applicant is in line with
the scope of the ﬁve-event stack maize. As no potential adverse environmental effects were identiﬁed,
case-speciﬁc monitoring was not considered necessary. The EFSA GMO Panel agrees with the reporting
intervals proposed by the applicant in its PMEM plans.
4. Overall conclusions
No new data on the single maize events Bt11, 59122, MIR604, 1507 and GA21 that would lead to a
modiﬁcation of the original conclusions on their safety were identiﬁed. The combination of maize events
Bt11, 59122, MIR604, 1507 and GA21 in the ﬁve-event stack maize did not give rise to issues – relating
to molecular, agronomic/phenotypic or compositional characteristics – regarding food and feed safety.
The newly expressed proteins in the ﬁve-event stack maize did not raise concerns for human and
animal health. The compositional data indicate that maize Bt11 9 59122 9 MIR604 9 1507 9 GA21 is
expected to be as nutritious as its conventional counterpart. This was conﬁrmed by the results of an
animal feeding study in chickens for fattening.
The EFSA GMO Panel considers that there is no reason to expect interactions that could impact on
food and feed safety. No safety concerns are foreseen for any subcombination of the individual events.
38 Dossier: Part I – Section D7.11.
39 Dossier: Part I – Section D9.11/Additional information: 4/4/2016.
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Considering the introduced traits and the outcome of the comparative analysis, the routes of
exposure and limited exposure levels, the EFSA GMO Panel concluded that the ﬁve-event stack maize
would not raise safety concerns in case of accidental release of viable GM maize seeds into the
environment, irrespective of possible interactions between the individual events within this ﬁve-event
stack maize.
Moreover, in the light of the scope of the application, the data available for various
subcombinations and the poor ability of maize to survive outside cultivated land, the EFSA GMO
Panel is of the opinion that any subcombinations of the individual events would not raise
environmental safety concerns. Post-market monitoring of food/feed derived from maize
Bt11 9 59122 9 MIR604 9 1507 9 GA21 or the 20 subcombinations is not considered necessary. The
EFSA GMO Panel considers the scope of the PMEM plan provided by the applicant is consistent with
the scope of this application. The EFSA GMO Panel agrees with the reporting intervals proposed by the
applicant in the PMEM plans.
The EFSA GMO Panel did not ﬁnd indications that the subcombinations, resulting from combination
of any of the single events included in the ﬁve-event stack maize, would raise safety concerns.
However, no speciﬁc data were submitted for the subcombinations included in the scope of this
application. For these subcombinations, the EFSA GMO Panel has drawn conclusions on a weight-
of-evidence approach, which identiﬁed uncertainties due to the absence of speciﬁc data.
In order to reduce these uncertainties and to conﬁrm assumptions made for the assessment of
these subcombinations, the EFSA GMO Panel considers that the applicant should provide relevant
information, if these subcombinations were to be created via targeted breeding approaches and
imported into the EU in the future. In this case, this information should focus on expression levels of
the newly expressed proteins.
A minority opinion expressed by an EFSA GMO Panel member is appended to this opinion.
Documentation provided to EFSA
1) Letter from the Competent Authority of Germany, received on 7 July 2011, concerning a
request for placing on the market of genetically modiﬁed maize Bt11 9 59122 9 MIR604 9
1507 9 GA21 submitted by Syngenta Crop Protection AG in accordance with Regulation
(EC) No 1829/2003 (application reference EFSA-GMO-DE-2011-99).
2) Acknowledgement letter dated 21 July 2009 from EFSA to the Competent Authority of
Germany.
3) Letter from EFSA to applicant dated 17 August 2011 requesting additional information
under completeness check.
4) Letter from EFSA to applicant dated 9 November 2011 requesting a consolidated version of
the application and clariﬁcations on the scope.
5) Letter from applicant to EFSA received on 12 December 2011 providing a timeline for
submission of responses.
6) Letter from applicant to EFSA received on 21 December 2011 providing additional
information under completeness check.
7) Letter from applicant to EFSA received on 21 December 2011 providing clariﬁcations on the
scope and a consolidated version of the application.
8) Letter from EFSA to applicant dated 25 January 2012 requesting additional information
under completeness check.
9) Letter from applicant to EFSA received on 15 March 2012 requesting clariﬁcations on the
progress of six Syngenta applications.
10) Letter from applicant to EFSA received on 2 April 2012 providing additional information
under completeness check.
11) Letter from EFSA to applicant dated 6 June 2012 providing clariﬁcations requested on 15
March 2012.
12) Letter from EFSA to applicant dated 14 June 2012 delivering the ‘Statement of Validity’ of
application for the placing on the market of genetically modiﬁed maize
Bt11 9 59122 9 MIR604 9 1507 9 GA21 submitted by Syngenta Crop Protection AG in
accordance with Regulation (EC) No 1829/2003.
13) Letter from EURL-GMFF to EFSA dated 20 June 2012 asking EFSA to stop the clock.
14) Letter from EFSA to applicant dated 22 June 2012 requesting additional information and
stopping the clock on behalf of the EURL-GMFF.
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15) Letter from EFSA to applicant dated 29 August 2012 re-starting the clock on behalf of the
EURL-GMFF.
16) Letter from EFSA to applicant dated 7 December 2012 requesting additional information
and stopping the clock.
17) Letter from applicant to EFSA received on 31 January 2013 providing a timeline for
submission of responses.
18) Letter from EFSA to applicant dated 5 February 2013 requesting additional information and
maintaining the clock stopped
19) Letter from EURL-GMFF to EFSA dated 27 March 2013 asking EFSA to stop the clock.
20) Letter from EFSA to applicant dated 2 April 2013 requesting additional information on
behalf of the EURL-GMFF maintaining the clock stopped.
21) Letter from applicant to EFSA received on 3 May 2013 providing additional information.
22) Letter from EFSA to applicant dated 23 September 2013 requesting additional information
and maintaining the clock stopped.
23) Letter from applicant to EFSA received on 4 November 2013 providing a timeline for
submission of responses.
24) Letter from EURL-GMFF dated 4 March 2014 asking EFSA to re-start the clock on behalf of
EURL-GMFF.
25) Letter from EFSA to applicant dated 6 March 2014 re-starting the clock on behalf of the
EURL-GMFF and keeping it stopped for EFSA.
26) Letter from EFSA to applicant dated 12 March 2014 requesting additional information and
maintaining the clock stopped.
27) Letter from applicant to EFSA received on 7 May 2014 providing a timeline for submission
of responses.
28) Letter from applicant to EFSA received on 23 June 2014 providing additional information
(the response includes info requested on 23/9/2013).
29) Letter from applicant to EFSA received on 28 July 2014 providing additional information
spontaneously.
30) Letter from applicant to EFSA received on 30 September 2014 providing additional
information spontaneously.
31) Letter from EFSA to applicant dated 27 October 2014 requesting additional information and
maintaining the clock stopped.
32) Letter from applicant to EFSA received on 21 November 2014 providing additional
information.
33) Letter from applicant to EFSA received on 28 November 2014 providing a timeline for
submission of responses.
34) Letter from applicant to EFSA received on 20 January 2015 providing a timeline for
submission of responses.
35) Letter from applicant to EFSA received on 27 May 2015 requesting clariﬁcations on an EFSA
request on Bioinformatics.
36) Letter from EFSA to applicant dated 18 June 2015 providing clariﬁcations requested
regarding Bioinformatics.
37) Letter from applicant to EFSA received on 21 July 2015 providing information regarding
sequencing of Events MIR604 and GA21.
38) Letter from applicant to EFSA received on 27 July 2015 providing additional information.
39) Letter from EFSA to applicant dated 18 September 2015 requesting additional information
and maintaining the clock stopped.
40) Letter from applicant to EFSA received on 24 September 2015 providing additional
information.
41) Letter from EFSA to applicant dated 7 December 2015 re-starting the clock.
42) Letter from applicant to EFSA received on 17 December 2015 providing complementary
information spontaneously.
43) Letter from EFSA to applicant dated 23 December 2015 requesting additional information
and stopping the clock.
44) Letter from applicant to EFSA received on 8 February 2016 providing a timeline for
submission of responses.
45) Letter from applicant to EFSA received on 4 April 2016 requesting a modiﬁcation of the
scope of the application.
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46) Letter from applicant to EFSA received on 4 April 2016 providing additional information.
47) Communication from EFSA to applicant re-starting the clock on 4 April 2016.
48) Letter from applicant to the German Competent Authority and to EFSA received on 4 April
2016 regarding the change of scope of the application.
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Abbreviations
ADF acid detergent ﬁbre
ANOVA analysis of variance
Bt Bacillus thuringiensis
CaMV cauliﬂower mosaic virus
Cry crystal protein
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EcoƩtat statistical consultancy in ecology, ecotoxicology and agriculture research
EFSA GMO Panel Panel on Genetically Modiﬁed Organisms of the European Food Safety Authority
ELISA enzyme-linked immunosorbent assay
EPSPS 5-enolpyruvylshikimate-3-phosphate synthase
ERA environmental risk assessment
EURL-GMFF European Union Reference Laboratory for GM Food & Feed
FA fatty acid
GM genetically modiﬁed
GMO genetically modiﬁed organism
IgE immunoglobulin E
LOQ limit of quantiﬁcation
NDF neutral detergent ﬁbre
OECD Organisation for Economic Co-operation and Development
ORF open reading frame
PAT phosphinothricin acetyltransferase
PCR polymerase chain reaction
PMEM post-market environmental monitoring
PMI phosphomannose isomerase
TDF total dietary ﬁbre
UTR untranslated region
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Appendix A – Minority opinion
Application EFSA-GMO-DE-2011-99
(Bt11 3 59122 3 MIR604 3 1507 3 GA21 maize)
Minority Opinion
J.M. Wal, Member of the EFSA GMO Panel
Rapporteur of AP 99 for Food/Feed safety assessment
Summary
Application (AP) 99 includes the ﬁve-event stack Bt11 9 59122 9 MIR604 9 1507 9 GA21 maize
and all sub-combinations that may derive from this stack independently of their origin. It is, however,
noteworthy that six sub-combinations are out of the scope of the AP by decision of the Applicant, but
the 20 other ones are still in the scope. This means that, according to the EU regulation, the adoption
of the ﬁve-event stack Bt11 9 59122 9 MIR604 9 1507 9 GA21 maize will, automatically and
simultaneously, result in the adoption of these 20 subcombinations.
This will apply if they are present by natural segregation during the cultivation of the authorized
ﬁve-event stack or if they are produced on their own in the future by targeted conventional breeding
techniques, using parental lines different of those used and assessed in the present AP, and imported
in the EU as independent stacks. No speciﬁc data regarding any of those 20 sub-combinations have
been provided by the Applicant, who also did not give a satisfactory rationale explaining the reasons
why those data are missing and/or why he would consider that they are not necessary for the risk
assessment.
This is a most important reason for expression of this minority opinion, considering that there
cannot be two kinds of risk assessment, a comprehensive one based on a complete set of data
and another one for which no speciﬁc data at all are available and which is based on assumptions and
indirect considerations deduced by the Panel by the so called “weight of evidence approach” and
extrapolation of data obtained for the single events, the ﬁve-event stack and other stacks that were
submitted and assessed in other applications. In addition to this matter of principle, in the present
case, this may result in uncontrolled risk for the health of human consumers in certain segments of the
population.
Presentation of AP 99
The intended uses of this ﬁve-event stack are to control lepidopteran and coleopteran maize pests
and provide tolerance to herbicides containing glufosinate ammonium or glyphosate.
The single events:
Bt11 (truncated Cry1Ab protein, PAT protein); 59122 (Cry34Ab1 protein+Cry35Ab1 protein, PAT
protein); MIR604 (mCry3A protein, PMI (Phospho Mannose Isomerase)); 1507 (Cry1F protein, PAT
protein); GA21 (mEPSPS protein), were assessed by EFSA.
In addition, 6 sub-combinations, i.e.:
MIR604 x GA21 (AP 48); Bt11 x GA21 (AP 49); Bt11 x MIR604 (AP 50); 1507 9 59122 (AP 15);
Bt11 x MIR604 x GA21 (AP 56) and Bt11 9 1507 9 59122 (AP 15), were also assessed by EFSA in
previous applications but they have been removed from the scope of AP 99 by the Applicant and are
thus not directly concerned by this risk assessment.
Then 20 “new” sub-combinations that have never been assessed before by EFSA and that may
have even not been produced yet, at least for some of them, are parts of AP 99 and of this risk
assessment. Their list is the following:
Bt11 9 MIR604 9 1507 9 GA21; Bt11 9 59122 9 MIR604 9 GA21; Bt11 9 59122 9 1507 9
GA21; 59122 9 MIR604 9 1507 9 GA21; Bt11 9 59122 9 MIR604 9 1507;
Bt11 9 59122 9 MIR604; Bt11 9 59122 9 GA21; Bt11 9 MIR604 9 1507; 59122 9 MIR604 9
1507; 59122 9 MIR604 9 GA21; 59122 9 1507 9 GA21; Bt11 9 1507 9 GA21; MIR604 9 1507
9 GA21; 59122 9 MIR604 x GA21
Bt11 9 59122; Bt11 9 1507; 59122 9 MIR604; 59122 9 GA21; MIR604 9 1507; 1507 9 GA21
No speciﬁc data has been provided for any of these 20 sub-combinations. In a response to the
Commission (1), the Applicant has presented a compilation of general considerations of different
nature to claim that those missing data were not necessary for the risk assessment.
Opinion on GM maize Bt113 591223MIR6043 15073 GA21 and its subcombinations
www.efsa.europa.eu/efsajournal 28 EFSA Journal 2016;14(8):4567
This list cannot be considered a consistent rationale. Moreover some arguments provided appear to
be contradictory.
It is thus mentioned in point ii)
“the Bt11 9 59122 9 MIR604 9 1507 9 GA21 maize and all of its sub-combinations
independently of their origin have been produced by conventional breeding crosses of the
GM maize single events Bt11, 59122, MIR604; 1507 and GA21 maize.”
and in point x): “The analysis of the protein expression level also conﬁrms that the
crossing of the GM maize single events Bt11, 59122, MIR604; 1507 and GA21 results in no interaction
between them in Bt11 9 59122 9 MIR604 9 1507 9 GA21 maize or the sub-combinations of
fewer of these events independently of their origin.”
In such case, if those data have been produced as stated by the Applicant, they should have been
provided.
Food/Feed safety assessment of AP 99
Comparative analyses
The Food/Feed Safety Assessment of the ﬁve-event stack has been performed according to the
EFSA Guidance Documents, 2006 and 2007 (2, 3). During the comparative analysis with the
conventional counterpart, a few differences were identiﬁed in the agronomic and phenotypic
characteristics and in the composition of grain and forage. They were not considered relevant for Food
and Feed safety and no further assessment was required.
As previously indicated, no speciﬁc data were provided for any of the 20 sub-combinations in the
scope of AP99.
Toxicological assessment of the newly expressed proteins.
EFSA has previously performed a toxicological assessment of the newly expressed proteins (NEPs)
individually in the context of the single event applications and no safety concerns were identiﬁed. The
3 insecticidal Bt proteins (i.e. produced by Bacillus thuringiensis), namely Cry1Ab, Cry1F, mCry3A, the
herbicide tolerant proteins, i.e. PAT, mEPSPS and the marker protein PMI are rapidly degraded by
pepsin in the conditions of the pepsin resistance test and their sequences show no signiﬁcant
homology to known protein toxins and allergens. They were therefore considered unlikely to present a
health risk to humans or animals and no further assessment, including a 28-day repeated dose toxicity
study, was required in the context of these applications.
However, a 14-day repeated dose toxicity study with the PAT protein was also performed and
provided by the Applicant in the context of the application on 59122 maize. It conﬁrmed the absence
of adverse effects.
The two Bt proteins Cry34Ab1 and Cry35Ab1 expressed in 59122 maize structurally differ from
Cry1Ab, Cry1F and Cry3A; they belong to the family of binary toxins and act synergistically. Therefore
they are used and expressed together in GM crops. Because of such characteristics, a 28-day toxicity
study was required by EFSA and it was performed by the Applicant using the mixture at a ratio
Cry34Ab1/Cry35Ab1 of ca. 25 (e.g. same as that expressed in the plant). No treatment-related effects
were observed.
It is noteworthy that Bt proteins such as Cry1Ab and those structurally and functionally similar have
a quite long history of use and are generally considered safe for mammals and particularly humans
because of their speciﬁc mode of action as insecticide (i.e. binding to speciﬁc receptors of insect gut
mucosa with high afﬁnity). However, side effects have been observed that may affect the immune
system following certain conditions of exposure. In particular a systemic and mucosal adjuvant activity
has been described in mice after high dose administrations of Cry1Ac by the intra gastric, intra
peritoneal and intra nasal routes.
Among other effects, an antibody response against an unrelated protein has been observed (for
review see 4). Because of these characteristics, Cry proteins such as Cry1Ac are being proposed as
mucosal adjuvant for increasing the efﬁcacy of vaccination. This issue is in relation with the doses of
administration although very little is known regarding the doseresponse relationship and the
manifestation of such an adjuvant activity in other Bt proteins than Cry1Ab and Cry1Ac. This issue has
been extensively discussed when assessing the single events and it has then been shown by different
research groups: i) that at the dose at which it is expressed in MON 810, Cry1Ab did not exert an
allergenic or an adjuvant activity (at least for the MON 810 cultivars that have been tested) and ii) that
the adjuvant activity would anyway differ from that of cholera toxin by its mode of action, which was
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at this time a major concern also expressed by some Member State Competent Authorities (for review
see 5). It was then concluded that in those single events the risk of adverse effects because of an
adjuvant activity was unlikely.
In the present ﬁve-event stack the levels of expression of the NEPs are similar to those measured
in the singles. The small increase observed in the concentration of the PAT protein does not raise
concerns for human and animal health given the outcomes of the repeated dose toxicological study. In
the case of Bt proteins, interactions have been described for their insecticidal activity but nothing is
known regarding possible interactions or particularly additive effects in their mode of action as
adjuvant in mammals. It differs from the mechanism of toxicity on insects and is now thought to be
due to a dose related effect on the innate immunity system. However given the data on the low levels
of expression of the NEPs in the ﬁve-event stack, it may be assumed from the literature that the
manifestation of an adjuvant activity by the combination of the 3 newly expressed Bt proteins is
unlikely even in the case of a possible additive effect. This conclusion also pertains to the sub-
combinations derived from the ﬁve-event stack by natural segregation during its cultivation.
There is thus no disagreement with the opinion adopted by the GMO Panel regarding the ﬁveevent
stack and the sub-combinations derived from this stack by natural segregation. The disagreement
derives from the conclusion on the 20 “sub-combinations independently of their origin” for which no
data have been provided. Some of these sub-combinations may already exist but they could mostly be
produced in the future by targeted conventional breeding with parental lines different from those used
in the 5 event stacks, the single events and sub-combinations previously assessed. Those new stacks
would be de facto authorized and could be imported in the EU since in its opinion the EFSA GMO
Panel concludes on the absence of safety concerns for the ﬁve-event stack maize and the twenty lower
subcombinations and does not require any further assessment.
No clear reservation which might question this assumption is made regarding a possible higher
expression level of the newly expressed Bt proteins compared to those actually measured in the 5
event stack, singles and other fully assessed applications.
However compositional data and actual concentrations of the NEPs are crucial to detect possible
unintended effect and achieve a grounded safety assessment. Indeed it has been shown that the
genetic background of the recipient plant has a major effect on Cry1Ac expression in GM cotton (6)
and therefore it may cause an important variability in Bt protein concentrations which might impact on
the safety. The risk of increased expression of the newly expressed Bt proteins in some of the “future”
sub-combinations and of a possible cumulative effect of their combination on the immune system (e.g.
resulting in an adjuvant activity) cannot be ruled out although it is difﬁcult to evaluate in the absence
of actual experimental data. Indeed the scope of AP 99 including the 20 sub-combinations in question
is for import and processing which suggests a limited exposure for consumers in the EU.
Nevertheless, should those sub-combinations (or some of them) be produced and commercialised
in the future, the resulting risk for human health, particularly in workers, might be higher than that of
singles or of the fully assessed Bt11 9 59122 9 MIR604 9 1507 9 GA21 maize.
In its opinion the GMO Panel states that it expects no adverse effect on human health; this
expectation or assumption is based on so called “weight of evidence approach” and extrapolation of the
data available for the singles, the ﬁve-event stack and some subcombinations, i.e. those already assessed
in previous applications that are out of the scope of AP 99. However what kind of extrapolation is being
made is not precisely deﬁned. The criteria, procedure and the level of conﬁdence that should be required
for this extrapolation are not given and there is no critical appraisal of its limitations. No evaluation of the
resulting uncertainty has been performed, e.g. using a probabilistic analysis, as recommended by the
Draft Guidance on Uncertainty in EFSA Scientiﬁc Assessment (Revised for Internal Testing) of the EFSA
Scientiﬁc Committee (7). These weaknesses may invalidate the general conclusion.
In addition one might consider that the role and remit of EFSA experts should be limited to check
the validity and relevance of the data provided and the reliability of the outcomes of the safety
assessment performed by the Applicant and not to develop arguments that could replace the missing
data instead of the Applicant.
Conclusion
It is not acceptable that the same weight and reliability is given to the assessment of a GM crop
for which a complete data set is available and can be comprehensively evaluated and to GM
crops for which no speciﬁc data are provided (i.e. the ﬁve-event stack and the whole package of 20
sub-combinations respectively in the present AP 99). In this case, the safety assessment of the 20
sub-combinations by the GMO Panel is based on assumptions that are not fully clariﬁed and justiﬁed
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and on so called weight of evidence approach and extrapolation which principle and limitations are
also not described and evaluated in terms of uncertainty. This is not in accordance with the above-
mentioned EFSA Guidance on Uncertainty.
The GMO Panel anticipates the absence of safety concerns and does not require that additional
speciﬁc data shall be provided to EFSA to guarantee the safety of these 20 subcombinations should
they be produced and imported to the EU market in the future.
Consequently the message delivered in this opinion is unclear since the EFSA GMO Panel concludes
that there is no safety concern (and therefore that a post-market monitoring programme of GM food/
feed is not necessary) for any of the 20 sub combinations despite of the data gap but at the same
time it “considers” that because of the uncertainty resulting from this data gap additional data should
be provided if those “safe” sub-combinations were to be produced in the future.
In addition, mixing considerations that are the remit and responsibility of risk assessment or of risk
management also adds to the confusion. Indeed recommendations might be a message for risk
managers but it is not sufﬁcient and the practical impact and regulatory value are unclear. It cannot
substitute a comprehensive quantitative uncertainty analysis.
This is not only a question of principle since in the present case a risk for the human health may
result from a possible over expression of NEPs if those sub-combinations were to be produced in other
genetic backgrounds than the ﬁve-event stack. Hopefully the risk might be low, but the uncertainty
could be much decreased if sufﬁcient speciﬁc data were provided by the Applicant before all “sub-
combinations independently of their origin” are approved; therefore, it is not up to the EFSA GMO
Panel Experts to a priori disregard potential unintended adverse effects and take responsibility for an
incompletely assessed risk. In the future, a better knowledge of the mechanisms of action of NEPs
(particularly of the different Bt proteins) and of the dose-(side) effect relationship would also allow
decreasing the uncertainty of the risk assessment. Allergic reactions in general and consequently food
allergy are dramatically increasing in the EU (and worldwide) and have become a most important
public health issue. The reasons are unclear but most specialists involve the changes in environmental
conditions and cultivated plant species. It would certainly be a shame if (re)questioning a possible role
of GM crops would thus be triggered by this case.
Those are the arguments and serious concerns that justify this minority opinion which should be
part of the risk assessment of AP 99. As stated in the Guidance on Uncertainty in EFSA Scientiﬁc
Assessment (7):
“Experts often have differing views on the same question. . . .. . . Where differences remain this is
part of scientiﬁc uncertainty and should be reﬂected in the assessment report, either within the
uncertainty analysis or, when appropriate, through EFSA’s procedure for minority opinions, so it can be
taken into account by decision-makers”.
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